Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sharing data for just three patients with the ultra-rare genetic disease familial chylomicronemia, Isis says starting with this indication will allow market entry one year earlier.